C Rodó1, A Suy2, E Sulleiro3, A Soriano-Arandes4, N Maiz2, I García-Ruiz2, S Arévalo2, A Rando3, A Anton3, É Vázquez Méndez5, M Garrido6, A Frick4, C Rodrigo7, T Pumarola3, E Carreras2. 1. Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari Vall d'Hebron, Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: crodo@vhebron.net. 2. Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari Vall d'Hebron, Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain. 3. Department of Microbiology, Hospital Universitari Vall d'Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain. 4. Tropical Medicine and International Health Unit, Hospital Universitari Vall d'Hebron, Barcelona, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain; Pediatric Infectious Diseases and Immunodeficiences Unit, Hospital Universitari Vall d'Hebron, Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain. 5. Department of Paediatric Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. 6. Department of Pathology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. 7. Pediatric Infectious Diseases and Immunodeficiences Unit, Hospital Universitari Vall d'Hebron, Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
Abstract
OBJECTIVES: The aim was to describe pregnancy outcomes after Zika virus (ZIKV) infection in a non-endemic region. METHODS: According to the Spanish protocol issued after the ZIKV outbreak in Brazil in 2015, all pregnant women who had travelled to high-burden countries were screened for ZIKV. Serological and molecular tests were used to identify ZIKV-infected pregnant women. They were classified as confirmed ZIKV infection when reverse transcription (RT) PCR tested positive, or probable ZIKV infection when ZIKV immunoglobulin M and/or immunoglobulin G and ZIKV plaque reduction neutralization tests were positive. Women found positive using molecular or serological tests were prospectively followed-up with ultrasound scans and neurosonograms on a monthly basis until delivery; magnetic resonance imaging and amniotic fluid testing were performed after signed informed consent. Samples of placenta, and fetal and neonatal tissues were obtained. RESULTS: Seventy-two pregnant women tested positive for ZIKV infection: ten were confirmed by RT-PCR, and 62 were probable cases based on serological tests. The prevalence of adverse perinatal outcomes was 33.3% (three out of nine, 95% CI 12.1-64.6%): two cases of congenital ZIKV syndrome (CZS) and one miscarriage, all born to women infected in the first trimester of gestation. All ZIKV-confirmed women had persistent viraemias beyond 2 weeks (median 61.50 days; IQR 35.50-80.75). Amniotic fluid testing was only positive in the two fetuses with anomalies. CONCLUSION: The prevalence of perinatal adverse outcomes for women with ZIKV-confirmed infection was 33.3%. Amniocentesis for ZIKV RT-PCR is recommended when fetal abnormalities are found. Intensive prenatal and postnatal follow-up of ZIKV-infected pregnancies is advised in confirmed cases.
OBJECTIVES: The aim was to describe pregnancy outcomes after Zika virus (ZIKV) infection in a non-endemic region. METHODS: According to the Spanish protocol issued after the ZIKV outbreak in Brazil in 2015, all pregnant women who had travelled to high-burden countries were screened for ZIKV. Serological and molecular tests were used to identify ZIKV-infected pregnant women. They were classified as confirmed ZIKV infection when reverse transcription (RT) PCR tested positive, or probable ZIKV infection when ZIKV immunoglobulin M and/or immunoglobulin G and ZIKV plaque reduction neutralization tests were positive. Women found positive using molecular or serological tests were prospectively followed-up with ultrasound scans and neurosonograms on a monthly basis until delivery; magnetic resonance imaging and amniotic fluid testing were performed after signed informed consent. Samples of placenta, and fetal and neonatal tissues were obtained. RESULTS: Seventy-two pregnant women tested positive for ZIKV infection: ten were confirmed by RT-PCR, and 62 were probable cases based on serological tests. The prevalence of adverse perinatal outcomes was 33.3% (three out of nine, 95% CI 12.1-64.6%): two cases of congenital ZIKV syndrome (CZS) and one miscarriage, all born to women infected in the first trimester of gestation. All ZIKV-confirmed women had persistent viraemias beyond 2 weeks (median 61.50 days; IQR 35.50-80.75). Amniotic fluid testing was only positive in the two fetuses with anomalies. CONCLUSION: The prevalence of perinatal adverse outcomes for women with ZIKV-confirmed infection was 33.3%. Amniocentesis for ZIKV RT-PCR is recommended when fetal abnormalities are found. Intensive prenatal and postnatal follow-up of ZIKV-infected pregnancies is advised in confirmed cases.
Authors: Elizabeth Centeno-Tablante; Melisa Medina-Rivera; Julia L Finkelstein; Heather S Herman; Pura Rayco-Solon; Maria Nieves Garcia-Casal; Lisa Rogers; Kate Ghezzi-Kopel; Mildred P Zambrano Leal; Joyce K Andrade Velasquez; Juan G Chang Asinc; Juan Pablo Peña-Rosas; Saurabh Mehta Journal: Viruses Date: 2021-01-18 Impact factor: 5.048
Authors: A E Ades; Antoni Soriano-Arandes; Ana Alarcon; Francesco Bonfante; Claire Thorne; Catherine S Peckham; Carlo Giaquinto Journal: Lancet Infect Dis Date: 2020-10-14 Impact factor: 25.071
Authors: Diana L Villazana-Kretzer; Kathryn McGuckin Wuertz; Daniel Newhouse; Jennifer R Damicis; Elisabeth M Dornisch; Kathleen M Voss; Antonio E Muruato; Jennifer A Paymaster; Stacey S Schmiedecke; Sarah M Edwards; Peter G Napolitano; Jennifer Tisoncik-Go; Nicholas Ieronimakis; Michael Gale Journal: Commun Biol Date: 2022-03-18
Authors: Antoni Soriano-Arandes; Marie Antoinette Frick; Milagros García López-Hortelano; Elena Sulleiro; Carlota Rodó; María Paz Sánchez-Seco; Marta Cabrera-Lafuente; Anna Suy; María De la Calle; Mar Santos; Eugenia Antolin; María Del Carmen Viñuela; María Espiau; Ainara Salazar; Borja Guarch-Ibáñez; Ana Vázquez; Juan Navarro-Morón; José-Tomás Ramos-Amador; Andrea Martin-Nalda; Eva Dueñas; Daniel Blázquez-Gamero; Resurrección Reques-Cosme; Iciar Olabarrieta; Luis Prieto; Fernando De Ory; Claire Thorne; Thomas Byrne; Anthony E Ades; Elisa Ruiz-Burga; Carlo Giaquinto; María José Mellado-Peña; Alfredo García-Alix; Elena Carreras; Pere Soler-Palacín Journal: Pathogens Date: 2020-05-07